Raymond James & Associates Buys 11,798 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Raymond James & Associates lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,235 shares of the company's stock after purchasing an additional 11,798 shares during the quarter. Raymond James & Associates owned 0.07% of Vaxcyte worth $9,283,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PCVX. Darwin Global Management Ltd. grew its stake in shares of Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company's stock worth $187,907,000 after buying an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. raised its holdings in Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock worth $665,152,000 after buying an additional 1,284,883 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company's stock worth $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock worth $524,117,000 after acquiring an additional 692,492 shares in the last quarter. Finally, Avoro Capital Advisors LLC bought a new position in Vaxcyte during the first quarter valued at about $39,278,000. 96.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of research reports. Leerink Partners increased their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Mizuho raised their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Needham & Company LLC increased their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Finally, BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $147.50.

Insider Transactions at Vaxcyte

In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 42,000 shares of the firm's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the transaction, the chief financial officer now owns 90,383 shares of the company's stock, valued at $10,429,294.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,098 shares of company stock valued at $9,937,773 over the last 90 days. Company insiders own 3.10% of the company's stock.

Vaxcyte Trading Up 0.5 %

NASDAQ PCVX traded up $0.55 on Wednesday, hitting $106.11. 822,468 shares of the company traded hands, compared to its average volume of 832,721. The business's 50 day moving average price is $107.29 and its 200-day moving average price is $85.10. Vaxcyte, Inc. has a 52-week low of $46.16 and a 52-week high of $121.06. The company has a market capitalization of $11.84 billion, a price-to-earnings ratio of -22.77 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same period in the prior year, the business posted ($0.70) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.